Skip to Content
MilliporeSigma
  • [The effectiveness of certain magnesium salts in nephrolithiasis caused by the use of sodium oxalate and celecoxib].

[The effectiveness of certain magnesium salts in nephrolithiasis caused by the use of sodium oxalate and celecoxib].

Urologiia (Moscow, Russia : 1999) (2013-05-15)
A A Spasov, I N Iezhitsa, M V Kharitonova, M S Kravchenko, G L Snigur, V B Pisarev
ABSTRACT

The study was aimed to evaluation the effect of different magnesium salts and their combinations with pyridoxine on a course of calcium-oxalate nephrolithiasis, which was modeled by adding the sodium oxalate (3% of weight of the diet) and selective cyclooxygenase-2 inhibitor celecoxib at a dose 100 mg/kg body weight to a diet for 4 weeks. Starting from the 2nd week of the experiment, the animals had received one of the following compounds: magnesium L-aspartate, magnesium chloride, and their combination with vitamin B6; magnesium sulfate and Magne B6 (magnesium lactate and vitamin B6) as comparators. 28 days after the start of the experiment, disorders progressed in the group receiving only celecoxib and oxalate-rich diet: the urine level of oxalate increased by 171% (p < 0,0001), crystalluria had increased (up to 105 crystals in 10 microml of urinary sediment, p < 0,0001), creatinine clearance decreased by 29%, compared to control (p = 0,087). Increasing calcium/magnesium and oxalate/creatinine ratios in urine by 16 and 189%, respectively, was observed. In the renal parenchyma of animals treated with sodium oxalate and celebrex, calcifications with a volume fraction of 4% were identified, whereas these changes were absent in intact animals. According to the degree of correction ofhyperoxaluria and elimination of calcium oxalate crystals, investigated salts showed similar efficacy, with the exception of magnesium sulfate, which less contributed the compensation of abnormalities in kidney and urinary. According to the data of morphological study, the volume fraction of calcifications was lowest in the groups receiving magnesium L-aspartate and Magne B6.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Lactic acid, natural, ≥85%
Sigma-Aldrich
Lactic acid, 85%, FCC
Sigma-Aldrich
Magnesium chloride solution, BioUltra, for molecular biology, ~0.025 M in H2O
Sigma-Aldrich
L-Aspartic acid hemimagnesium salt dihydrate, ≥97.0% (KT)
Sigma-Aldrich
Oxalic acid, puriss. p.a., anhydrous, ≥99.0% (RT)
Sigma-Aldrich
Oxalic acid, 98%
Sigma-Aldrich
Oxalic acid, ReagentPlus®, ≥99%
Sigma-Aldrich
Magnesium chloride solution, BioUltra, for molecular biology, 2 M in H2O
Sigma-Aldrich
Lactic acid, meets USP testing specifications
Sigma-Aldrich
Magnesium chloride solution, PCR Reagent, 25 mM MgCI2 solution for PCR
Sigma-Aldrich
Magnesium chloride solution, for molecular biology, 1.00 M±0.01 M
Sigma-Aldrich
L-Aspartic acid, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%
SAFC
L-Aspartic acid
Sigma-Aldrich
L-Aspartic acid, BioXtra, ≥99% (HPLC)
Sigma-Aldrich
DL-Aspartic acid, ≥99% (TLC)
Sigma-Aldrich
L-Aspartic acid, reagent grade, ≥98% (HPLC)
Supelco
L-Aspartic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-Aspartic acid, BioUltra, ≥99.5% (T)
Sigma-Aldrich
Magnesium chloride solution, BioUltra, for molecular biology, ~1 M in H2O
Supelco
Oxalic acid concentrate, 0.1 M (COOH)2 (0.2N), eluent concentrate for IC
Sigma-Aldrich
Oxalic acid, purified grade, 99.999% trace metals basis
Sigma-Aldrich
Oxalic acid, SAJ first grade, ≥97.0%
Sigma-Aldrich
Magnesium chloride solution, 0.1 M
Supelco
Lactic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Oxalic acid solution, 0.05 M
Sigma-Aldrich
Oxalic acid solution, 0.5 M
Supelco
L-Aspartic acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
DL-Lactic acid, ~90% (T)
Supelco
Sodium oxalate, reference material for titrimetry, certified by BAM, >99.5%
Sigma-Aldrich
Magnesium chloride, powder, <200 μm